Genovis AB. (4/13/21). "Press Release: Genovis and Waters Collaborate to Develop Efficient Workflows for Biopharmaceutical Characterization".

	Organisation	Genovis AB
	Group	Genovis (Group)
	Organisation 2	Waters Corporation (NYSE: WAT)
	Group	Waters (Group)
	Product	mass spectrometry-based analysis of biopharmaceutical
	Product 2	SmartEnzymes™
	Person	Olsson, Fredrik (Genovis 201906 CEO)
	Person 2	Mazzeo, Jeffrey R. (Jeff) (Scitara 202206– Chief Marketing Officer before Waters)

Firms Working to Co-Develop Automated Biotherapeutic Characterization Workflows, Combining Genovis SmartEnzymes™ and Waters LC-MS Instrumentation.

> Collaboration intended to bring speed and simplicity to bio-characterization workflows

> Automated workflows to cut the time and effort required to monitor critical quality attributes of biotherapeutics in regulated laboratories

> Waters and Genovis share mutual goal to advance the science behind the analysis of glycoproteins and protein therapeutics

Genovis and Waters (NYSE:WAT) are formally collaborating to develop and market complete routine biopharmaceutical characterization workflows based on Genovis SmartEnzymes™ and the Waters™ BioAccord™ LC-MS System, Andrew+ pipetting robot. The goal of the collaboration is to develop automated workflows for the rapid and consistent characterization of critical quality attributes (CQAs) of monoclonal antibodies (mAbs) and other protein-based drugs in bioprocess development, formulation, stability testing and quality control (QC).

“The BioAccord SmartMS™ system and the Andrew+ aligns perfectly with our strategies and vision at Genovis to bring simplified, robust and automated enzyme-driven workflows to the biopharma industry,” said Fredrik Olsson, CEO, Genovis AB. “The enzymatic workflows that we will develop in collaboration with Waters will help our customers in their efforts to bring safe and novel therapeutics to patients, faster.”

“Biologics analysis is an area that is ripe for improvement. What takes analytical scientists several days to do, should take hours or minutes instead,” said Jeff Mazzeo, Vice President, Global Marketing and Scientific Operations, Waters Corporation. “Today, up-front sample preparation is a major bottleneck to productivity, largely due to the number of manual steps involved and the outmoded technology by which samples are readied for analysis. By combining Genovis’ SmartEnzymes with automation, liquid chromatography/time-of-flight mass spectrometry and application-specific software workflows from Waters, we intend to move biotherapeutic analysis forward in ways never thought possible.”

The workflows in development are based on the pairing of the Waters BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes and will focus on addressing the application needs of GxP laboratories in the following areas:

> Product variant analysis [e.g. glycosylation, oxidation]
> Bioprocess stability monitoring
> Biosimilar glycosylation analysis

Additional Resources

Visit the Waters web site: BioAccord LC-MS System for Biopharmaceuticals
Watch the video: Multi-Attribute Method Overview
Visit the Genovis AB website for information on Genovis SmartEnzymes
Visit the AndrewAlliance website for information on the Andrew+ Pipetting Robot
Visit Genovis Blog

About Waters Corporation (www.waters.com)

Waters Corporation (NYSE:WAT), the world's leading specialty measurement company, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food and environmental sciences for more than 60 years. With more than 7,400 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries. Waters, BioAccord, SmartMS, Andrew Alliance and waters_connect are trademarks of Waters Corporation.

Waters Contact: Brian J. Murphy, PR Manager, Corporate Communications Waters Corporation, brian_j_murphy@waters.com, +1 508-482-2614

Genovis’ business concept is to apply its knowledge and customer driven innovation to design and provide tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes™ all over the world in innovative product formats that facilitate development and quality control of biological drugs. The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (US). Genovis shares are listed on Nasdaq First North Growth Market and Erik Penser Bank is the Company’s Certified Adviser, certifiedadviser@penser.se, tel: +46 (0)8-463 83 00.

For more information, please contact: Fredrik Olsson, CEO, Genovis AB, Telephone: +46 (0)46-10 12 33, Email: fredrik.olsson@genovis.com

Record changed: 2023-06-05